Health news
The presence of obesity modifies the association of menopausal age and incidence of heart failure (HF), with the risk for development of HF becoming significantly higher with worsening obesity. These findings were published in the…
Patients with heart failure (HF) discharged from the hospital who received a telemedicine or in-person follow-up had better outcomes than patients who did not receive prompt HF healthcare during the COVID-19 pandemic, according to results…
Positive topline results were announced from a phase 3 study evaluating mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy (HCM) who are eligible for septal reduction therapy (SRT). Mavacamten is an oral, selective allosteric inhibitor…
Patients with heart failure (HF) may be at increased risk for cancer and cancer-related mortality, according to findings from a community-based cohort study published in JACC: CardioOncology. For the study, researchers sourced data from anonymized…
The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for omecamtiv mecarbil for the treatment of heart failure with reduced ejection fraction (HFrEF). Omecamtiv mecarbil is an investigational, selective, small molecule…
Although clinical trials have demonstrated favorable cardiovascular and kidney effects from use of sodium-glucose cotransporter 2 (SGLT2) inhibitors, clinicians appear to be underprescribing these drugs to patients with chronic kidney disease (CKD), a real-world study…
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy. Aficamten is an investigational oral, selective, small molecule cardiac myosin inhibitor designed to reduce…
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy. Aficamten is an investigational oral, selective, small molecule cardiac myosin inhibitor designed to reduce…
The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application for empagliflozin to reduce the risk of cardiovascular (CV) death plus hospitalization for heart failure (HF) in adults with…
Among patients with cardiovascular diseases who have received an implantable cardiac assistive device, women, individuals with lower income, and those who are divorced are at increased risk for having a more difficult time adjusting to…
© 2005-2021 Top-Meds - All rights reserved. Our website services, content, and products are for informational purposes only. Top-Meds does not provide medical advice, diagnosis, or treatment. | Medical News 2021